MENU
Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
May 08, 2023

MDGL Stock Price Target: 21% Upside Expected

MDGL, the stock of Madrigal Pharmaceuticals, has been showing signs of a bullish pattern since March 14, 2023. A Broadening Bottom pattern has emerged, which is a bullish reversal pattern. This pattern indicates that the stock has been undergoing increased volatility, with wider price swings, but is ultimately trending upwards.

This pattern was confirmed on April 24, 2023, when the stock broke out of the pattern's resistance level. The breakout was accompanied by strong volume, indicating that there was significant buying pressure, which is a positive sign for investors.

The current confidence level to reach the target price of 369.58 USD is 90%. This means that there is a high likelihood that the stock will reach this level in the near future. The distance to the target price is currently 21%, which represents a significant upside potential.

Investors who want to capitalize on this bullish pattern can consider the breakout price of 307.08 USD as an entry point. This is the price level at which the stock broke out of the pattern's resistance level and is therefore considered a strong buy signal.

The target (exit) price of 369.58 USD represents a potential gain of 20.3% from the breakout price. This is a significant return on investment and represents a good opportunity for investors who are looking to enter the market.

The Broadening Bottom pattern that has emerged in MDGL is a bullish reversal pattern that indicates the stock is trending upwards. The breakout of the pattern's resistance level on April 24, 2023, accompanied by strong volume, confirms this bullish trend. The current confidence level to reach the target price of 369.58 USD is high, and the distance to the target price represents a significant upside potential. Investors who are looking to capitalize on this trend can consider the breakout price of 307.08 USD as an entry point and set a target (exit) price of 369.58 USD.

Related Ticker: MDGL

MDGL's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for MDGL turned positive on November 05, 2025. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2025. You may want to consider a long position or call options on MDGL as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

MDGL moved above its 50-day moving average on November 04, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MDGL crossed bullishly above the 50-day moving average on November 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 167 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MDGL moved out of overbought territory on December 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MDGL broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.790) is normal, around the industry mean (27.055). P/E Ratio (0.000) is within average values for comparable stocks, (52.394). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.879). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (17.153) is also within normal values, averaging (318.757).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 58 to 107.98B. VRTX holds the highest valuation in this group at 107.98B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 55%. TCBPY experienced the highest price growth at 219%, while DOSEF experienced the biggest fall at -95%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was 45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 57
SMR Rating: 91
Profit Risk Rating: 93
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
MDGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MDGL showed earnings on November 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
276
Web
http://www.madrigalpharma.com
Interact to see
Advertisement
A powerful recession signal is flashing red: the Leading/Lagging Ratio has plunged to levels not seen since 2008. As markets grow turbulent, smart investors are turning to Tickeron’s AI trading agents to spot opportunities and stay ahead of the downturn.
#trading#artificial_intelligence
AI trading bots are no longer just experimental—they’re outperforming traditional strategies. Discover how bots trading ITA, TSM, META, and others achieved over 40% annual returns and what this means for the future of investing.
FingerMotion (FNGR) is making waves in 2025 with a 52% stock surge, strategic AI expansion into Indonesia, and strong retail momentum. Learn how traders are using correlation analysis, inverse ETFs, and Tickeron’s AI tools to navigate FNGR’s dynamic moves.
#artificial_intelligence#trading
Ferrari (RACE) is accelerating in 2025 with a 25% YTD gain, strong earnings, and bullish momentum fueled by innovation and Lewis Hamilton’s F1 move. Discover how Tickeron’s AI tools help traders capitalize on this luxury stock’s high-performance potential.
Intel’s stock is down 64%, but a bold turnaround under new CEO Lip-Bu Tan and the upcoming 18A chip rollout could spark a rebound. This article explores Intel’s financials, strategic shifts, and how AI tools from Tickeron help traders navigate the volatility.
#artificial_intelligence
Dogecoin (DOGE) fell 12.78% in five days, rattled by whale activity, Musk headlines, and ETF rumors. Is a breakout coming—or more downside? Explore key trends, technical levels, and how Tickeron’s AI bots help traders navigate DOGE’s next move.
The week of June 2-6, 2025, saw financial markets demonstrate resilience amid U.S.-China trade tensions and key economic data releases.
Tesla, Inc. (TSLA), a global leader in electric vehicles (EVs) and artificial intelligence (AI)-driven technologies, has been a focal point for investors in 2025.
#artificial_intelligence#trading
As artificial intelligence continues to reshape the financial industry, AI-powered trading agents have emerged as influential tools in portfolio management and speculative trading.
#investment#artificial_intelligence
Johnson & Johnson (JNJ), a global leader in healthcare, remains a cornerstone of stability in the stock market, known for its diversified portfolio spanning pharmaceuticals, medical devices, and consumer health products. As of June 5, 2025,
Roma Green Finance Limited (ROMA), a Hong Kong-based company specializing in environmental, social, and governance (ESG) advisory services, has emerged as a compelling player in the financial markets in 2025.
Amazon (NASDAQ: AMZN) remains a cornerstone of the technology and e-commerce sectors, consistently driving innovation and market influence.
#artificial_intelligence
Overview of AAPL Stock Performance Apple Inc. (AAPL) has long been a cornerstone of the technology sector, commanding a market capitalization of approximately $3.01 trillion as of June 8, 2025.
ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…
Tickeron, a leader in AI-driven financial solutions, announces the launch of its latest AI trading robot designed for five high-profile stocks: Amazon.com, Inc. (AMZN), Taiwan Semiconductor Manufacturing Company, Ltd. (TSM), Walmart Inc. (WMT), Google LLC (GOOG), and Meta Platforms Inc. (META).
MicroAlgo Inc. ($MLGO), a company focused on developing advanced algorithms and AI-driven solutions, has garnered attention in the financial markets due to its volatile price movements and potential for significant upside.
The SPDR S&P 500 ETF Trust (SPY) is one of the most widely traded exchange-traded funds (ETFs) in the world, designed to track the performance of the S&P 500 Index.
Tickeron, a leader in AI-driven financial solutions, proudly announces the exceptional performance of its XAR AI Trading Agent, achieving a remarkable +62% return and an 84.16% profitable trade rate for the SPDR S&P Aerospace & Defense ETF (XAR).
#artificial_intelligence#trading
GitLab Inc. (GTLB), a leading web-based DevOps lifecycle tool, has captured significant investor attention in 2025 due to its robust performance and strategic advancements in AI integration.
The week of June 9-13, 2025, was characterized by significant market volatility driven by both positive developments in US-China trade relations and escalating geopolitical tensions in the Middle East.